Multiple Sclerosis Drug Market Analysis

Medication Type (Oral, Injection)

The multiple sclerosis drug market is segmented and analyzed for demand and supply by medication type into oral and injection. The oral segment is expected to hold the largest market size by the end of 2037, owing to its better efficacy and favorable safety profile against other available treatments. Most oral MS therapies currently on the market have been granted marketing approvals by regulatory agencies. For instance, Cipla Inc. received approval from the United States Food and Drug Administration for Tecfidera (dimethyl fumarate DR capsules), an oral drug to treat the relapsing forms of multiple sclerosis.

Our in-depth analysis of the global market includes the following segments:

By Drug	Immunomodulators Immunosuppressants Interferons Others
By Type	Clinically Isolated Syndrome Relapse-Remitting MS Primary Progressive MS Secondary Progressive MS
By Medication Type	Oral Injection
By Treatment	Medications Stem Cell Therapy Physical Therapy Plasma Exchange
By End User	Hospitals Specialty Clinics Homecare Others

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of multiple sclerosis drug is evaluated at USD 25.89 billion.

The multiple sclerosis drug market size was over USD 25.07 billion in 2024 and is expected to exceed USD 42.07 billion by the end of 2037, growing at over 4.2% CAGR during the forecast period i.e., between 2025-2037. Factors such as, higher prevalence of multiple sclerosis, advancement in research and development, higher instances of women having multiple sclerosis and government efforts for the treatment will impel the market growth.

North America industry is anticipated to hold largest share by 2037, impelled by rising burden of multiple sclerosis among the population and a higher probability of women getting multiple sclerosis in the region.

The major players in the market include Biogen, Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Merck KGaA., Janssen Pharmaceuticals Companies of Johnson & Johnson, Bristol-Myers Squibb Company, Cipla Inc.

Multiple Sclerosis Drug Market Analysis